Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN – Get Rating) has received an average recommendation of “Buy” from the eleven research firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $152.60.
Several research firms recently issued reports on BHVN. HC Wainwright reiterated a “buy” rating and set a $160.00 target price on shares of Biohaven Pharmaceutical in a research report on Friday, January 7th. Mizuho increased their price target on Biohaven Pharmaceutical from $144.00 to $154.00 and gave the company a “buy” rating in a research note on Thursday, March 3rd. Finally, Morgan Stanley dropped their price target on Biohaven Pharmaceutical from $148.00 to $146.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 6th.
Large investors have recently modified their holdings of the business. National Bank of Canada FI purchased a new stake in Biohaven Pharmaceutical during the fourth quarter worth about $28,000. Elkhorn Partners Limited Partnership acquired a new position in shares of Biohaven Pharmaceutical during the fourth quarter worth about $48,000. Harbor Investment Advisory LLC grew its position in shares of Biohaven Pharmaceutical by 25.4% during the fourth quarter. Harbor Investment Advisory LLC now owns 587 shares of the company’s stock worth $81,000 after buying an additional 119 shares in the last quarter. Montag A & Associates Inc. acquired a new position in shares of Biohaven Pharmaceutical during the third quarter worth about $96,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Biohaven Pharmaceutical during the fourth quarter worth about $104,000. Institutional investors own 88.03% of the company’s stock.
Biohaven Pharmaceutical (NYSE:BHVN – Get Rating) last released its earnings results on Friday, February 25th. The company reported ($3.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.07) by ($0.94). The company had revenue of $190.01 million during the quarter, compared to analysts’ expectations of $175.54 million. During the same period in the prior year, the company earned ($3.62) EPS. The company’s quarterly revenue was up 441.1% compared to the same quarter last year. Research analysts predict that Biohaven Pharmaceutical will post -8.51 EPS for the current year.
About Biohaven Pharmaceutical (Get Rating)
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
- Get a free copy of the StockNews.com research report on Biohaven Pharmaceutical (BHVN)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.